



# *In vitro* assessment of the cytotoxic effects of novel RGD analogues

Anelia Balacheva<sup>1</sup>, Ivan Iliev<sup>2</sup>, Roumyana Detcheva<sup>1</sup>, Tatyana Dzimbova<sup>1</sup>, Tamara Pajpanova<sup>1\*</sup>, Evgeny Golovinsky<sup>1</sup>

<sup>1</sup> Institute of Molecular Biology "Roumen Tsanev", Bulgarian Academy of Sciences, Acad. G. Bonchev Str., block 21, Sofia 1113, Bulgaria

<sup>2</sup> Institute of Experimental Morphology, Pathology and Anthropology with Museum, Bulgarian Academy of Sciences, Acad. G. Bonchev Str., block 25, Sofia 1113, Bulgaria

## Abstract

The RGD sequence is present in many extracellular matrix proteins and intracellular proteins, including caspases. Synthetic RGD peptides may affect adhesion, migration and tumour metastasis, or directly induce apoptosis. Several RGD peptides were synthesized, and their anti-adhesive and cytotoxic properties were analyzed *in vitro*. Here we present the cytotoxic activities of RGD, R(NO<sub>2</sub>)GD, CavGD and RGD-OMe on non-tumour 3T3 cells and tumour cell lines HepG2 and MCF-7. The cell growth inhibitory effects of RGD-OMe are significantly higher than those of RGD on the cell lines used. Evidently the modification in the carboxylic group of RGD with simple esterification increases the cell growth inhibitory effects of the parent compound.

**Citation:** Balacheva A, Iliev I, Detcheva R, Dzimbova T, Pajpanova T, Golovinsky E. *In vitro* assessment of the cytotoxic effects of novel RGD analogues. *BioDiscovery* 2012; **4**: 1; DOI: 10.7750/BioDiscovery.2012.4.1

**Copyright:** © 2012 Balacheva et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, provided the original authors and source are credited.

**Received:** 31 July 2012; **Revised:** 13 October 2012; **Accepted:** 16 October 2012; **Available online/Published:** 23 October 2012

**Keywords:** RGD, cytotoxic activity, canavanine

\***Corresponding Author:** Tamara Pajpanova, e-mail: tamara@bio21.bas.bg

**Conflict of Interests:** No potential conflict of interest was disclosed and there is not any competing financial interest in relation to the work described.


## Introduction

Among the peptide family, short peptides are very appealing for drug discovery and development because of their cost-effectiveness, possibility of oral administration, and simplicity to perform molecular structural and quantitative structure-activity studies [1]. Small peptides are under development as possible anti-tumour agents as well. Examples of these are peptides with RGD (L-argininylglycyl-L-aspartic acid) or NGR (L-aspartylglycine-L-arginine) motifs presented in fibronectin, laminin, vitronectin, fibrinogen and collagens [2,3]. The discovery of the minimal peptide sequence RGD, which plays a prominent role in cell adhesion via integrin interaction, has led to a large increase in biomedical and


biomaterials research on this motif. RGD peptides are commonly known as antimetastatic agents and are able to decrease the number of spontaneous and experimental metastases in *in vivo* models [4-7]. Moreover, descriptions exist of some of their *in vitro* activities, like inhibition of tumour cell adhesion to extracellular matrix proteins and the inhibition of migration in a three dimensional gel [6, 8, 9].

Various RGD-containing peptides have been increasingly developed for adapting to versatile applications including tumor imaging and therapy, drug delivery vector, targeted gene transfer, and biomaterial or tissue engineering. Significant progress has been





**Figure 2.** HPLC-chromatograms of peptides 3 and 4. Chromatographic conditions: column: Atlantis™dC<sub>18</sub>, 4.6×150 mm, particle size 5µm, mobile phase: acetonitrile/deionised water 40/60 (v/v), column and sample temperature: 25°C, flow rate: 1ml/min, UV detection - 206 nm.



**Figure 3.** Effect of RGD and RGD-OMe on growth of 3T3, HepG2 and MCF-7 cells after 24 h of treatment. Cell cytotoxicity determined by MTT assay is expressed as per cent of dead cells and presented as mean  $\pm$  SD (n=6), \*\*\*P<0.001, \*\*P<0.01, \*P<0.05, ANOVA-test, versus the control group. C – control.

(1-4) is demonstrated by calculating the half maximal inhibitory concentrations ( $IC_{50}$  values), shown in Table 1.  $IC_{50}$  values of 1-3, in 3T3, HepG2 and MCF-7 are >2 mM (Table 1).  $IC_{50}$  values of RGD-OMe in 3T3, HepG2 and MCF-7 are 0.758, 0.524 and 0.927 respectively. Evidently HepG2 is the most sensitive of the three cell lines to the cytotoxic effects of the RGD-OMe.

**Table 1.** Comparative cytotoxic activity of RGD and its analogues R(NO<sub>2</sub>)GD, CavGD and RGD-OMe in 3T3, HepG2 and MCF-7 cells after 24 h treatment (MTT-dye reduction assay).

Peptides	Mean $IC_{50}$ values (mM)*		
	3T3	HepG2	MCF-7
RGD	>2	>2	>2
R(NO <sub>2</sub> )GD	>2	>2	>2
CavGD	>2	>2	>2
RGD-OMe	0.758±0.0504	0.524±0.0766	0.927±0.1066

HepG2 cells, treated with RGD and RGD-OMe were investigated for damages in their genomic DNA by neutral variant of Comet assay. The obtained by us Comet assay data confirmed that the RGD and RGD-OMe revealed certain DNA damaging activity, i.e. genotoxicity, which was increasing with the modifications of the compound (results not published). In an attempt to look deeper in the details of the observed genotoxicity we searched for consequence of the compounds on the cell cycle. The FACS analysis, however, has not proposed evidence of distinctive influence of the studied compounds on the stages of cell cycle. This result show that even strongly pronounced the genotoxic activity of the compounds is not connected with certain check point of the cell cycle (results not published).

## Discussion

Peptides containing unusual amino acids are used in a multitude of applications including structural activity studies, diagnostics, and new drug discovery, improvements in bioavailability, molecular markers, and biologically active pharmaceuticals.

We decided to carry out various structural modifications on N- and C-terminal of the RGD molecule [18]. We chose for example, unnatural amino acid L-canavanine (Cav), as a promising candidate for the synthesis of RGD analogues, instead of the basic residue Arg.

As shown by several authors, Cav a structural analogue of Arg, possesses growth retardation activity toward tumor cells in culture and experimental tumors *in vivo* [19-21]. We supposed that modification with the structural analogue and antimetabolite of Arg, will improve the antitumor activity of the parent molecule.

The cytotoxic activities of peptides 2 and 3 on 3T3 and HepG2 cells were examined (results not shown) but only the highest concentration used (2 mM) revealed cell growth inhibitory effect. Next, we decided to perform an experiment with C-terminal modified RGD. For this purpose we synthesized RGD-OMe 4.

The results showed that the cell growth inhibitory effects of 4 are significantly higher than those of RGD on the three cell lines. Evidently, the modification in the carboxylic group of RGD with simple esterification increases the cell growth inhibitory effects of the parent compound.

The effect of RGD-OMe is higher in the case of the tumor cells HepG2 in comparison with non-tumour cells 3T3. This observation suggests that the modification in the carboxylic group is significant for the antitumour action of RGD.

According to our recent investigations, as well as our further work, which is in progress, these new members of RGD are easily transformed into derivatives with improved pharmacological properties, or they can be used as building blocks for combinatorial peptide libraries.

## Materials and Methods

### Synthesis

The peptides 1 and 2 were synthesized manually by the solid phase method using Fmoc chemistry on (2-Chloro) chlorotrityl resin (Iris Biotech GmbH, Germany) using Fmoc/tBu methodology. Fmoc groups were removed using 20% piperidine in DMF. Coupling reactions were performed using Fmoc-amino acid/HBTU/HOBt/DIEA/resin in molar ratio of 3/3/3/9/1. The coupling and deprotection reactions were checked by the Kaiser test. Peptide removal from the resin and the removal of side chain protection groups were performed using 95% TFA with 0.3% TES treatment. The synthesis of RGD-OMe was prepared by classical solution procedure using mixed anhydride coupling reactions. The final products were purified by gel filtration on a Sephadex G-10 column. The peptide purity was monitored on a RP-HPLC column Atlantis<sup>TM</sup>dC<sub>18</sub>, 4.6×150 mm, particle size 5µm, mobile phase: acetonitrile/deionised water 40/60 (v/v), at 25°C, flow rate: 1ml/min, and UV detection - 206 nm. The correct molecular masses were confirmed by ESI-MS. For R(NO<sub>2</sub>)GD, **GF** - C<sub>12</sub>H<sub>21</sub>O<sub>7</sub>N<sub>7</sub>, [MH]<sup>+</sup> calculated -375.34, [MH]<sup>+</sup> observed -375.36; CavGD, **GF** - C<sub>11</sub>H<sub>21</sub>O<sub>6</sub>N<sub>6</sub>, [MH]<sup>+</sup> calculated -333.32, [MH]<sup>+</sup> observed -333.19; RGD-OMe, **GF** - C<sub>13</sub>H<sub>24</sub>O<sub>5</sub>N<sub>6</sub>, [MH]<sup>+</sup> calculated -344.37, [MH]<sup>+</sup> observed -344.59.

### Cell cultures

The 3T3 (standard mouse embryonic fibroblast cell line), MCF-7 (human breast cancer cell line) and HepG2

(human liver hepatocellular carcinoma cell line) cells were cultured in Dulbecco Modified Eagle's medium (DMEM) (Gibco, Austria) supplemented with 10% fetal bovine serum (Gibco, Austria), 100 U/ml penicillin (Lonza, Belgium) and 0.1 mg/ml streptomycin (Lonza, Belgium) under a humidified 5% CO<sub>2</sub> atmosphere at 37°C. Plastic flasks supplied by Greiner, Germany, were used to grow the cells. Cells were trypsinized using Trypsin-EDTA (FlowLab, Australia) when they reached approximately 80% confluence. For experiments the cells in exponential phase of growth after treatment with Trypsin-EDTA were seeded into 96-well plates (Greiner, Germany) in a concentration 2x10<sup>4</sup> cells/well. 24 hours incubation post seeding (under a humidified 5% CO<sub>2</sub> atmosphere at 37°C) allowed the cells to attach to the wells.

### Cytotoxicity assay

The cultivated cells were treated with RGD and its analogues (2-4) in a wide concentration range (2 - 0.015 mM). Untreated cells were used as controls. Empty wells were blank controls. Cytotoxicity was measured by colorimetric assay based on tetrasolium salt MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) (Sigma Chemical Co.). The MTT assay is based on the protocol first described by Mossman (1983). In this

assay, living cells reduce the yellow MTT to insoluble purple formazan crystals. The peptides were dissolved in dimethyl sulfoxide (DMSO). The final concentration of DMSO in samples did not affect the viability of the cells. The assay was performed 24 hours after treatment with the amino acid analogues. For this purpose, MTT solution was prepared at 5 mg/ml in PBS and was filtered through a 0.2 µm filter. Then 1 ml of MTT solution was added to 15 ml DMEM and 100 µl of this solution were added into each well, including the cell free blank wells. Then the plates were further incubated for 3 hours to allow MTT to be metabolized and the supernatant was removed. 100 µl/well DMSO/etanol (1/1) was added. The plates were placed in a microtitre-plate shaker for 10 min at room temperature to thoroughly mix the purple formazan into the solvent. ELIZA plate reader (TECAN, Sunrise TM, Grodig/Sazburg, Austria) was used for reading the results. Optical density (OD) was determined at a wavelength of 540 nm and a reference wavelength of 620 nm. Cell cytotoxicity determined by MTT assay was expressed as per cent of dead cells:

$$\% \text{ cytotoxicity} = \frac{(1 - (\text{OD sample} - \text{OD blank control}) / (\text{OD control} - \text{OD blank control})) \times 100}{100}$$

PrizmaPlot.4 (ANOVA-test) was used for statistical analysis.

## References

1. Ung P, Winkler DA. Tripeptide Motifs in Biology: Targets for Peptidomimetic Design *J Med Chem* 2011; **54**:1111-1125
2. Ruoslahti E, Pierschbacher MD. New perspectives in cell adhesion: RGD and integrins. *Science* 1987; **238**: 491-497.
3. Sasaki M, Kleinman HK, Huber H, Deutzmann R, Yamada Y. Laminin, a multidomain protein. The A chain has a unique globular domain and homology with the basement membrane proteoglycan and the laminin B chains. *J Biol Chem* 1988; **263**: 16536-16544.
4. Humphries M J, Olden K, Yamada KM. A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. *Science* 1986; **233**: 467-470.
5. Saiki I, Murata J, Iida J, Sakurai T, Nishi N, Matsuno K, Azuma I. Antimetastatic effects of synthetic polypeptides containing repeated structures of the cell adhesive Arg-Gly-Asp (RGD) and Tyr-Ile-Gly-Ser-Arg (YIGSR) sequences. *Br J Cancer* 1989; **60**: 722-728.
6. Saiki I, Murata J, Makabe T, Nishi N, Tokura S, Azuma, I. Inhibition of tumor angiogenesis by a synthetic cell-adhesive polypeptide containing the Arg-Gly-Asp (RGD) sequence of fibronectin, poly(RGD). *Jpn J Cancer Res* 1990; **81**: 668-675.
7. Saito N, Mitsuhashi M, Hayashi T, Narumo C, Nagata H, Soyama K, Kameoka S, Harumiya S, Fujimoto D. Inhibition of hepatic metastasis in mice treated with cell-binding domain of human fibronectin and angiogenesis inhibitor TNP-470. *Int J Clin Oncol* 2001; **6**: 215-220.
8. Murata J, Saiki I, Ogawa R, Nishi N, Tokura S, Azuma I. Molecular properties of poly(RGD) and its binding capacities to metastatic melanoma cells. *Int J Pept Protein Res* 1991; **38**: 212-217.
9. Sogabe T, Nishimura S, Chung YS, Sowa M. Role of tripeptide Arg-Gly-Asp (RGD) on adhesiveness of human pancreatic cancer cell, PANC-1 to extracellular matrix. *Nippon Rinsho* 1995; **53**: 1648-1652.
10. Meyer A, Auernheimer J, Modlinger A, Kessler H. Targeting RGD recognizing integrins: drug development, biomaterial research, tumor imaging and targeting. *Curr Pharm Des* 2006; **12**:2723-2747.
11. Yamamoto, Y., Tsutsumi, Y. and Mayumi, T. Molecular design of bioconjugated cell adhesion peptide with a water-soluble polymeric modifier for enhancement of antimetastatic effect. *Curr Drug Targets* 2002; **3**: 123-130.
12. Tsuchiya Y, Sawada S, Tsukada K, Saiki I. A new pseudo-peptide of Arg-Gly-Asp (RGD) inhibits intrahepatic metastasis of orthotopically implanted murine hepatocellular carcinoma. *Int J Oncol* 2002; **20**: 319-324.
13. Saiki I, Yoneda J, Igarashi, Y, Aoki M, Kusunose N, Ono K, Azuma I. Antimetastatic activity of polymeric RGD peptides conjugated with poly(ethylene glycol). *Jpn J Cancer Res* 1993; **84**: 558-565.
14. Fujii H, Nishikawa N, Komazawa H, Orikasa A, Ono M, Itoh I, Murata J, Azuma I, Saiki I. Inhibition of tumor invasion and metastasis by peptidic mimetics of Arg-Gly Asp (RGD) derived from the cell recognition site of fibronectin. *Oncol Res* 1996; **8**: 333-342.
15. Mukhopadhyay S, Barnés CM, Haskel A, Short SM, Barnes KR, Lippard SJ. Conjugated Platinum(IV)-Peptide Complexes for Targeting Angiogenic Tumor Vasculature. *Bioconjugate Chem.* 2008; **19**: 39-49.
16. Raha S, Paunesku T, Woloschak G. Peptide-mediated cancer targeting of nanoconjugates. *WIREs Nanomedicine and Nanobiotechnology* 2011; **3**: 269-281.

17. Wang W, Borchardt R T, Wang B. Orally active peptidomimetic RGD analogs that are glycoprotein IIb/IIIa antagonists. *Curr Med Chem.* 2000; **7**:437–453.
18. Pajpanova T, Georgiev K, Dzimbova T, Georgieva M, Staneva D, Miloshev G. In vitro Assessment of the Cytotoxic Effects of Novel RGD-Mimetics, in *Peptides: Building Bridges Proceedings of the 22<sup>nd</sup> American Peptide Symposium* (Lebl M. ed.), 2011, Prompt Scientific Publishing, San Diego, USA, pp. 190-191.
19. Bence AK, Worthen DR, Adams VR, Crooks PA. The antiproliferative and immunotoxic effects of L-canavanine and L-canaline. *Anticancer Drugs* 2002; **13**: 313–320.
20. Miersh J, Grancharov K, Pajpanova T, Neumann D, Tabakova S, Stoev S, Krauss G-J, Golovinsky E. Synthesis and biological activity of canavanine hydrazide derivatives. *Amino Acids* 2000; **18**: 41-59.
21. Dzimbova T, Iliev I, Georgiev K, Detcheva R, Balacheva A, Pajpanova T. In vitro assessment of the cytotoxic effects of sulfo-arginine analogues and their hydrazide derivatives in 3T3 and HepG2 cells. *Biotechnol & Biotechnol Eq* 2012; **26**: 180-184.